CLINICAL TRIALS PROFILE FOR PYLARIFY
✉ Email this page to a colleague
All Clinical Trials for PYLARIFY
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05394259 ↗ | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | Not yet recruiting | Lantheus Medical Imaging | Early Phase 1 | 2022-11-30 | To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer, HCC, or pancreatic cancer |
| NCT05394259 ↗ | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | Not yet recruiting | M.D. Anderson Cancer Center | Early Phase 1 | 2022-11-30 | To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer, HCC, or pancreatic cancer |
| NCT05568537 ↗ | Prostate MRI and Pylarify PSMA PET/CT | Not yet recruiting | Sirisha Nandalur, MD | Phase 4 | 2022-11-01 | This is a voluntary research study to find out how using technology including advanced magnetic resonance imaging (MRI) and prostate-specific membrane antigen - positron emission tomography (PSMA-PET) scan imaging, in addition to combined prostate treatment using radiation therapy, brachytherapy (internal radiation treatment using small radioactive seeds placed inside the body) and androgen deprivation therapy (drug therapy to suppress hormones) can help doctors see, track and predict tumor response to treatment for prostate cancer patients. Participation in this study will consist of radiation planning and simulation, magnetic resonance imaging (MRI) and positron emission tomography and computed tomography scan (PET/CT). One MRI and PSMA PET/CT scan will be done prior to the start of first external beam radiation therapy (EBRT) fraction. At mid-treatment prior to the second brachytherapy fraction, an MRI and PSMA PET/CT will be done. A third scan will be performed after 75% testosterone recovery or 12 months post androgen deprivation therapy (ADT) [whichever comes first]. |
| NCT05919329 ↗ | Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy | Not yet recruiting | Oregon Health and Science University | Phase 4 | 2024-05-01 | This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy. |
| NCT05919329 ↗ | Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy | Not yet recruiting | Progenics Pharmaceuticals, Inc. | Phase 4 | 2024-05-01 | This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy. |
| NCT05919329 ↗ | Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy | Not yet recruiting | OHSU Knight Cancer Institute | Phase 4 | 2024-05-01 | This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy. |
| NCT06074510 ↗ | PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer | Recruiting | Lantheus Medical Imaging | Phase 4 | 2024-02-08 | The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer. Participants will receive a single dose of PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours after PYLARIFY injection. Participants with positive study scan results that are suspicious for prostate cancer outside of the prostate gland may be asked to undergo additional diagnostic test(s) and/or recommend certain treatment(s) for prostate cancer within 2 to 90 days after the study scan. Participants will be monitored for up to 12 months to collecting information about treatment they receive for prostate cancer and results of regular PSA blood draws if ordered by doctors for up to 12 months after the study scan. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PYLARIFY
Condition Name
Clinical Trial Locations for PYLARIFY
Trials by Country
Clinical Trial Progress for PYLARIFY
Clinical Trial Phase
Clinical Trial Sponsors for PYLARIFY
Sponsor Name
